Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 20,640,000 | 10,590,000 | 5,240,000 | 6,244,800 | 5,581,700 |
| Depreciation Amortization | 1,997,000 | 1,767,000 | 1,527,000 | 1,522,500 | 1,547,600 |
| Income taxes - deferred | -1,707,000 | -2,683,000 | -2,341,000 | -2,185,200 | -802,300 |
| Accounts receivable | -7,000,000 | -2,155,000 | -2,451,000 | -299,600 | -1,278,300 |
| Accounts payable and accrued liabilities | 10,187,000 | 2,609,000 | 4,274,000 | 1,692,000 | -1,013,800 |
| Other Working Capital | -8,093,000 | -5,384,000 | -3,055,000 | -800 | -1,012,600 |
| Other Operating Activity | 789,000 | 4,074,000 | 1,046,000 | 612,000 | 4,343,600 |
| Operating Cash Flow | $16,813,000 | $8,818,000 | $4,240,000 | $7,585,700 | $7,365,900 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | N/A | 14,000 | -36,100 |
| PPE Investments | -7,841,000 | -5,058,000 | -3,448,000 | -1,854,300 | -1,309,800 |
| Net Acquisitions | N/A | N/A | N/A | -327,200 | -747,400 |
| Purchase Of Investment | -645,000 | -677,000 | -731,000 | -600,200 | -929,900 |
| Sale Of Investment | 964,000 | 374,000 | 508,000 | 342,200 | 800,000 |
| Other Investing Activity | -3,450,000 | -3,941,000 | -3,482,000 | -1,337,400 | -644,300 |
| Investing Cash Flow | $-10,972,000 | $-9,302,000 | $-7,153,000 | $-3,762,900 | $-2,867,500 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -4,338,000 | -1,852,000 | 4,691,000 | 1,498,000 | N/A |
| Debt Issued | 13,167,000 | 11,417,000 | 3,959,000 | N/A | 2,406,800 |
| Debt Repayment | -778,000 | -664,000 | N/A | -1,560,000 | -1,905,400 |
| Common Stock Repurchased | -4,108,000 | -2,500,000 | -750,000 | -1,500,000 | -1,250,000 |
| Dividend Paid | -5,384,000 | -4,680,000 | -4,069,000 | -3,535,800 | -3,086,800 |
| Other Financing Activity | -772,000 | -491,000 | -335,000 | -308,900 | -295,900 |
| Financing Cash Flow | $-2,213,000 | $1,230,000 | $3,496,000 | $-5,406,700 | $-4,131,300 |
| Exchange Rate Effect | 372,000 | -297,000 | 169,000 | -167,600 | -205,700 |
| Beginning Cash Position | 3,268,000 | 2,819,000 | 2,067,000 | 3,818,500 | 3,657,100 |
| End Cash Position | 7,268,000 | 3,268,000 | 2,819,000 | 2,067,000 | 3,818,500 |
| Net Cash Flow | $4,000,000 | $449,000 | $752,000 | $-1,751,500 | $161,400 |
| Free Cash Flow | |||||
| Operating Cash Flow | 16,813,000 | 8,818,000 | 4,240,000 | 7,585,700 | 7,365,900 |
| Capital Expenditure | -7,841,000 | -5,058,000 | -3,448,000 | -1,854,300 | -1,309,800 |
| Free Cash Flow | 8,972,000 | 3,760,000 | 792,000 | 5,731,400 | 6,056,100 |